Safety and Side Effects of Once-Weekly GLP-1 Injections for Type 2 Diabetes
Once-weekly GLP-1 receptor agonists (dulaglutide, exenatide ER, semaglutide) are generally well-tolerated, with GI side effects being most common and usually transient.
Quick Facts
What This Study Found
Once-weekly GLP-1 RAs have manageable safety profiles dominated by gastrointestinal side effects, with differences between agents that inform treatment selection.
Key Numbers
30 trials; 3 QW GLP-1 RAs; GI AEs most common; semaglutide DRC 3.0% vs 1.8% placebo (SUSTAIN 6); low hypoglycemia/pancreatitis/neoplasm rates
How They Did This
Narrative review comparing phase 3 clinical trial safety data for dulaglutide, exenatide ER, and semaglutide.
Why This Research Matters
With GLP-1 RAs increasingly prescribed for diabetes and obesity, clinicians need clear safety comparisons to choose the right agent for each patient.
The Bigger Picture
As GLP-1 RAs become a cornerstone of diabetes treatment, understanding their distinct safety profiles helps optimize prescribing and improve patient outcomes.
What This Study Doesn't Tell Us
Based on clinical trial data which may not capture all real-world safety signals. Head-to-head comparisons between agents are limited.
Questions This Raises
- ?Which once-weekly GLP-1 RA has the best tolerability profile?
- ?How do real-world side effect rates compare to clinical trial data?
- ?Are there long-term safety concerns not captured in clinical trials?
Trust & Context
- Key Stat:
- 3 agents Once-weekly GLP-1 RAs compared for safety: dulaglutide, exenatide ER, and semaglutide
- Evidence Grade:
- Review of phase 3 clinical trial data. Reliable safety information from well-designed trials.
- Study Age:
- Published in 2020. Additional safety data have accumulated with widespread clinical use.
- Original Title:
- Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.
- Published In:
- Journal of clinical pharmacy and therapeutics, 45 Suppl 1(Suppl 1), 43-60 (2020)
- Authors:
- Trujillo, Jennifer
- Database ID:
- RPEP-05173
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are the most common side effects of weekly GLP-1 shots?
Nausea, vomiting, and diarrhea are the most common side effects, especially when starting treatment. These are usually mild and improve over time as the body adjusts to the medication.
Which weekly GLP-1 shot has the fewest side effects?
Each agent has a slightly different profile. The review compares them to help clinicians choose the best option for individual patients based on their specific health conditions and tolerance.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05173APA
Trujillo, Jennifer. (2020). Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.. Journal of clinical pharmacy and therapeutics, 45 Suppl 1(Suppl 1), 43-60. https://doi.org/10.1111/jcpt.13225
MLA
Trujillo, Jennifer. "Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.." Journal of clinical pharmacy and therapeutics, 2020. https://doi.org/10.1111/jcpt.13225
RethinkPeptides
RethinkPeptides Research Database. "Safety and tolerability of once-weekly GLP-1 receptor agonis..." RPEP-05173. Retrieved from https://rethinkpeptides.com/research/trujillo-2020-safety-and-tolerability-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.